|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
2955 Virtual Way, 480, Vancouver, British Columbia V5M 4X6, CA
|
|
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease.
NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin.
NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory.
NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
|
NervGen Pharma Corp. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used NervGen Pharma Corp. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact NervGen Pharma Corp. customer service number in your country click here to find.
Michael Kelly is the CEO of NervGen Pharma Corp.. To contact Michael Kelly email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.